7/102 sources · 2 publishersUpdated Nov 14, 10:34 UTC
Leerink Partners upgrades enGene Therapeutics to Outperform with $5 price target
Leerink Partners raised its rating on enGene Therapeutics (ENGN) from Market Perform to Outperform and set a new price target of $5.00 per share. The upgrade suggests a potential upside of about 119.3% from the prior close of $2.28. The analyst note also mentions that ENGN’s recent price moves have shown a median swing of 4.0% in either direction over the past 19 sessions.
Why it matters
The $5 target implies a large upside, which may attract buying interest and support the stock price. The rating upgrade signals stronger analyst confidence in ENGN’s prospects.
Key facts
- 1Leerink Partners upgraded enGene Therapeutics to Outperform from Market Perform. tradingview.com
- 2The new price target set by Leerink Partners is $5.00 per share. tradingview.com
- 3The $5 target represents a 119.3% upside from the November 12 close of $2.28. tradingview.com
- 4ENGN’s median price move over the 19 sessions following prior headlines was 4.0% in either direction. quantisnow.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.